Alerta De Seguridad para HeartWare HVAD Pumps

Según Department of Health, este evento ( alerta de seguridad ) involucró a un dispositivo médico en Hong Kong que fue producido por HeartWare Incorporation.

¿Qué es esto?

Las alertas proporcionan información importante y recomendaciones sobre los productos. Aunque se haya emitido una alerta, esto no significa necesariamente que el producto se considera peligroso. Las alertas de seguridad, dirigidas a trabajadores de la salud y a usuarios, pueden incluir retiro de equipos. Pueden ser escritas por los fabricantes, pero también por funcionarios del área de salud.

Más información acerca de la data acá
  • Tipo de evento
    Safety alert
  • Fecha
  • Fecha de publicación del evento
  • País del evento
  • Fuente del evento
  • URL de la fuente del evento
  • Notas / Alertas
    Hong Kong data is current through September 2018. All of the data comes from the Department of Health (Hong Kong), except for the categories Manufacturer Parent Company and Product Classification.
    The Parent Company and the Product Classification were added by ICIJ.
    The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of data from the U.S. and Hong Kong.
  • Notas adicionales en la data
    Medical Device Safety Alert
  • Causa
    Medical device safety alert: heartware hvad pumps medical device manufacturer, heartware incorporation, has issued a medical device safety alert concerning its hvad pumps. the affected devices are identified as follows:- model number: 1104gb serial number: sterile, un-implanted stock in inventory with serial numbers prior to hw25838 the manufacturer has reviewed certain complaints related to the hvad system and announced a voluntary recall of specified implant kits (pumps) in hospital inventory, which may be more susceptible to electrical faults if the driveline becomes contaminated. according to the manufacturer, contamination of the driveline-to-controller connector can occur during the implant procedure or post operatively from fluid ingress into the driveline. connector contamination of the driveline has been seen to occur most often in the first 30 days post implant. affected devices that have already been implanted into a patient are not subject for removal. the presence of fluid or foreign material at the driveline/controller connector may impact the function of the pump and controller. specifically, foreign material at the driveline/controller connector could lead to electrical faults and connection failures. in these scenarios, potential risks include interruption of circulatory support due to a pump stop, which could cause serious injury or death. the manufacturer has implemented manufacturing process improvements designed to prevent driveline connector contamination in new implant kits. users are advised not to attempt to repair or service any components of the heartware system. if the heartware system equipment malfunctions, they should promptly contact their local representative. according to the local supplier, the affected serial numbers are not distributed in hong kong. if you are in possession of the affected products, please contact your supplier for necessary actions. posted on 12 august 2016.


  • Modelo / Serial
  • Descripción del producto
    Medical Device Safety Alert: HeartWare HVAD Pumps
  • Manufacturer


  • Empresa matriz del fabricante (2017)
  • Comentario del fabricante
    “If our surveillance systems identify a potential performance issue, our personnel promptly evaluate the problem, including, when appropriate, conducting root cause investigations and internal testing to assess whether the product continues to meet specifications and defined performance criteria,” Medtronic told ICIJ in a statement. “In some cases, based on this evaluation, Medtronic may determine that a recall is necessary.” The company said that it communicates with healthcare providers and/or patients and provide recommendations to address such issues. Medtronic noted that these communications can include letters, emails, calls, press releases, physician notifications and social media postings, as well as informing the FDA and other regulators of the actions.
  • Source